glp-1 and parkinson's disease Glucagon-like peptide-1 (GLP-1) receptor agonists neuroinflammation: Implications for neurodegenerative treatment GLP-1 and Parkinson's Disease: A

April 1, 2026: Lawsuits Involving Ozempic & Other GLP-1s Climb to Over 3,500 Ozempics manufacturer, Novo Nordisk, and one other GLP-1 company are facing about 3,546 lawsuits in an active, federally consolidated MDL filed by former patients and their loved ones

ClinicalTrials.gov Identifier: NCT03659682

Step 2: Talk To Your Doctor Bring a list of your feelings and symptoms Ask if your medication could be playing a role Be honestit helps your provider help you Step 3: Get Support Consider talking to a therapist Reach out to support groups Stay connected with friends and family The Bottom Line: Whats True, Whats Not

A separate 72-week trial found that obese or overweight patients using Mounjaro, the most effective weight loss injection available, lost between 15% and 20% of their body weight

GLP-1 Microdosing has been shown to optimize metabolism, improve cardiovascular health, reduce inflammation, and promote cellular health, often with reduced or no side effects